- Home
- AUPH vs AVBP Comparison
AUPH vs AVBP Comparison
Compare AUPH & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- AVBP
- Stock Information
- Founded
- AUPH 1993
- AVBP 2021
- Country
- AUPH Canada
- AVBP United States
- Employees
- AUPH N/A
- AVBP N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- AVBP
- Sector
- AUPH Health Care
- AVBP
- Exchange
- AUPH Nasdaq
- AVBP NYSE
- Market Cap
- AUPH 1.1B
- AVBP 862.8M
- IPO Year
- AUPH 1999
- AVBP 2024
- Fundamental
- Price
- AUPH $8.86
- AVBP $21.63
- Analyst Decision
- AUPH Strong Buy
- AVBP Strong Buy
- Analyst Count
- AUPH 2
- AVBP 8
- Target Price
- AUPH $11.50
- AVBP $38.38
- AVG Volume (30 Days)
- AUPH 1.9M
- AVBP 484.4K
- Earning Date
- AUPH 07-31-2025
- AVBP 08-13-2025
- Dividend Yield
- AUPH N/A
- AVBP N/A
- EPS Growth
- AUPH N/A
- AVBP N/A
- EPS
- AUPH 0.27
- AVBP N/A
- Revenue
- AUPH $247,295,000.00
- AVBP N/A
- Revenue This Year
- AUPH $12.15
- AVBP $85.82
- Revenue Next Year
- AUPH $18.31
- AVBP N/A
- P/E Ratio
- AUPH $33.04
- AVBP N/A
- Revenue Growth
- AUPH 29.20
- AVBP N/A
- 52 Week Low
- AUPH $5.20
- AVBP $15.47
- 52 Week High
- AUPH $10.67
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- AUPH 64.10
- AVBP 47.74
- Support Level
- AUPH $7.36
- AVBP $19.71
- Resistance Level
- AUPH $9.10
- AVBP $22.32
- Average True Range (ATR)
- AUPH 0.44
- AVBP 1.32
- MACD
- AUPH 0.10
- AVBP -0.20
- Stochastic Oscillator
- AUPH 89.53
- AVBP 31.89
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.